i. Remus Pharmaceuticals is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). They also provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
ii. The Company is majorly engrossed in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical finished formulations and products. Depending upon business requirments, they get finished pharmacuetical formulations manufactured on loan license or contract manufacturing. Such manufacturing is on principle to principle basis. The company has presence through registered and/or under registration products in countries namely Bhutan, Bolivia, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Kuwait, Madagascar, Malaysia, Hong kong, Myanmar, Panama, Trinidad and Tobago, Uzbekistan, Venezuela, Vietnam.
iii. They deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.
iv. Their product portfolio consists of 429 products. They operate under different brand names across the globe. The company has 295 products registered in total 13 countries and total 134 products are under process of registration in 16 countries, which shall boost the growth of thecompany.
v. They have business to business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
vi. Their Core business can be divided in following categories:
a) Marketing and Distribution of approved finished formulations in various countries
b) Trading of Active Pharmaceutical Ingredients
c) Technical Consultancy on preparation of reports on pharmaceutical dossiers
1. Experienced Promoters and Management Team
2. Wide range of Products
3. Strategic Location of Contract Manufacturing Facilities
4. Diversified business operations and revenue base
Objects of the Remus Pharmaceuticals Limited IPO:
The Issue Proceeds from the Fresh Issue will be utilized towards the following objects:
1. To Meet Working Capital Requirements
2. Funding investments for acquisitions and general corporate purposes
3. To meet Public Issue Expenses
Remus Pharmaceuticals Limited IPO Details:
||May 17 2023
||May 19 2023
|| ₹ 10 Per Equity Share
||Book Built Issue IPO
|| ₹ 1150-1229 Per Equity Share
||May 29 2023
Discussion on Remus Pharmaceuticals Limited IPO: